8 Sources of evidence considered by the Committee

8 Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Aberdeen HTA Group:

  • Cummins E, Scott N, Rothnie K et al. Dapagliflozin for the treatment of type 2 diabetes. Aberdeen HTA Group, Institute of Applied Health Sciences, University of Aberdeen, November 2012.

B. The Decision Support Unit (DSU) reports for this appraisal are:

  • Davis S, Sheard J. A review of the Bristol‑Myers Squibb/AstraZeneca economic model on the cost-effectiveness of dapagliflozin, November 2012.

  • Davis S. Dapagliflozin for the treatment of type 2 diabetes: Additional analyses requested by the Committee following the second meeting, April 2013.

C. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I. Manufacturers/sponsors:

  • Bristol Myers‑Squibb and AstraZeneca

II. Professional/specialist and patient/carer groups:

  • Black Ethnic Minority Diabetes Association

  • Diabetes UK

  • National Diabetes Nurses Consultant Group

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

III. Other consultees:

  • Department of Health

  • Welsh Assembly Government

  • NHS Middlesbrough

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • Aberdeen HTA Group

  • Boehringer Ingelheim and Lilly UK (linagliptin)

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Eli Lilly (exenatide, insulin)

  • Health Improvement Scotland

  • National Institute for Health Research Health Technology Assessment Programme

  • Novo Nordisk (insulin, liraglutide)

  • Pfizer (glipizide)

D. The following individuals were selected from clinical specialist and patient expert nominations from the consultees and commentators. They gave their expert personal view on dapagliflozin by attending Committee discussions and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Professor Eric Kilpatrick, Consultant in Chemical Pathology, Hull and East Yorkshire Hospitals NHS Trust nominated by organisation representing Royal College of Pathologists – clinical specialist (first Committee meeting)

  • Dr Peter Winocour, Consultant Physician and Clinical Director of Diabetes and Endocrine Services nominated by organisation representing Association of British Clinical Diabetologists (ABCD) and Royal College of Physicians (RCP) – clinical specialist (first Committee meeting)

  • Professor Jiten Vora, Consultant Physician and Endocrinologist nominated by organisation representing Royal College of Physicians and Association of British Clinical Diabetologists – clinical specialist (second Committee meeting)

  • Mrs Cathy Moulton, Clinical Advisor nominated by organisation representing Diabetes UK – patient expert

  • Ms Aderonke Kuti, Executive Director, nominated by organisation representing Black and Ethnic Minority Diabetes Association – patient expert

E. The following individuals were nominated as NHS Commissioning experts by the selected Commissioning Group allocated to this appraisal. They gave their expert/NHS commissioning personal view on dapagliflozin by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Ms Joanne Linton, Assistant Director Medicines Management selected by NHS Tees – NHS commissioning expert

  • Dr Victoria Ononeze, Public Health Specialist selected by NHS Tees – NHS commissioning expert

F. Representatives from the following manufacturers attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Bristol Myers‑Squibb and AstraZeneca (dapagliflozin)

  • National Institute for Health and Care Excellence (NICE)